Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats

被引:41
作者
Singh, Yogendra [1 ]
Singh, Kulwinder [2 ]
Sharma, P. L. [1 ]
机构
[1] ISF Coll Pharm, Dept Pharmacol, Moga 142001, Punjab, India
[2] Baba Farid Univ Hlth Sci, Univ Inst Pharm, Faridkot 151203, Punjab, India
关键词
Aliskiren; AVE; 0991; DOCA-salt hypertension; Mas-receptor; ANGIOTENSIN-CONVERTING-ENZYME; BLOOD-PRESSURE; RENAL DAMAGE; ALISKIREN; TRANSPORT; AVE-0991; STIMULATION; SECRETION; MECHANISM; TUBULE;
D O I
10.1007/s11010-012-1489-2
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
To investigate the combined effect of aliskiren, a renin inhibitor, and AVE 0991, a Mas-receptor agonist, in experimental hypertension (HT) in rats. HT was produced by administration of deoxycorticosterone acetate (DOCA) and mean arterial blood pressure (MABP) was assessed by tail-cuff method. Treatments were started from 4th week onwards and were continued for 9 days. A significant increase in MABP was noted after 1 week in DOCA control rats, as compared with the base line value. A stable HT developed after 4 weeks of DOCA administration. Treatments with aliskiren and AVE 0991 alone, dose-dependently decreased MABP in DOCA-treated rats. Further, combination of low doses of aliskiren and AVE 0991 significantly reduced MABP, as compared with DOCA control rats and with either drug alone in low doses. It may be concluded that treatment with aliskiren produced down-regulation of both harmful Ang II-AT1-receptor and survival Ang(1-7)/Mas-receptor axis of RAAS. Treatment with combination of low doses of aliskiren and AVE 0991, for the first time, has been shown to produce synergistic blood pressure lowering effect. Therefore, combination of renin inhibitor with Mas-receptor agonist may prove beneficial for the treatment of hypertensive patients.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 41 条
[1]
Renin inhibition with aliskiren: where are we now, and where are we going? [J].
Azizi, M ;
Webb, R ;
Nussberger, J ;
Hollenberg, NK .
JOURNAL OF HYPERTENSION, 2006, 24 (02) :243-256
[2]
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME [J].
Benter, IF ;
Yousif, MHM ;
Anim, JT ;
Cojocel, C ;
Diz, DI .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (02) :H684-H691
[3]
Antihypertensive effects of angiotensin-(1-7) [J].
Chappell, MC ;
Iyer, SN ;
Diz, DI ;
Ferrario, CM .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1998, 31 (09) :1205-1212
[4]
Cheung Bernard M Y, 2006, J Clin Hypertens (Greenwich), V8, P93, DOI 10.1111/j.1524-6175.2006.04895.x
[5]
The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats [J].
Collister, JP ;
Hendel, MD .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2003, 4 (03) :176-179
[6]
Endothelial dysfunction in DOCA-salt hypertension - Possible involvement of prostaglandin endoperoxides [J].
Cordellini, S .
GENERAL PHARMACOLOGY, 1999, 32 (03) :315-320
[7]
Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats [J].
Dobrzynski, E ;
Wang, C ;
Chao, J ;
Chao, L .
HYPERTENSION, 2000, 36 (06) :995-1001
[8]
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].
Donoghue, M ;
Hsieh, F ;
Baronas, E ;
Godbout, K ;
Gosselin, M ;
Stagliano, N ;
Donovan, M ;
Woolf, B ;
Robison, K ;
Jeyaseelan, R ;
Breitbart, RE ;
Acton, S .
CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9
[9]
STIMULATION OF BASOLATERAL NA+-HCO-3 COTRANSPORTER BY ANGIOTENSIN-II IN RABBIT RENAL-CORTEX [J].
EIAMONG, S ;
HILDEN, SA ;
JOHNS, CA ;
MADIAS, NE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (02) :F195-F203
[10]
Counterregulatory actions of angiotensin-(1-7) [J].
Ferrario, CM ;
Chappell, MC ;
Tallant, EA ;
Brosnihan, KB ;
Diz, DI .
HYPERTENSION, 1997, 30 (03) :535-541